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Abstract
The ETV6 (TEL1) gene encodes a member of the ETS family of 
transcriptional regulators. It represents one of the most frequently disrupted 
genes in haematological malignancies, with over 50 different translocations 
described. Moreover, deletion, silencing or truncating mutations have also been 
reported, suggesting a potential tumor suppressor function. Recent studies 
have shown that ETV6 plays a broad and complex role in early hematopoiesis, 
impacting on the development of multiple lineages, providing new insights into 
how its perturbation contributes to disease. 
Keywords: ETV6; TEL1; ETS; Hematopoiesis; Leukemia 
its C-terminus is encoded by exons 6 and 7 flanking a central domain 
encoded by exon 5 (Figure 1).
The PNT domain is responsible for homo or heterodimerization 
with a range of proteins, including the closely-related ETV7 protein, 
the ETS family member FLI1 and the ubiquitin-conjugating enzyme 
UBC9 [6,7,11,12]. This domain is required for the repression of target 
genes [13], and also mediates the nuclear export of ETV6, thereby 
regulating its activity [14]. The positively charged ETS domain is 
responsible for binding to DNA [15,16]. The less conserved central 
domain contributes to the repression activity of ETV6 [17-21].
In several studies ETV6 has been identified as a strong 
transcriptional repressor [17,18]. This has been mapped to the PNT 
and central domains. PNT domain-mediated repression has been 
shown to be dependent on interaction with the SPM domain of 
L3MBTL1 (human homolog of the Drosophila Lethal3 Malignant 
brain tumor protein), a member of polycomb group of chromatin-
associated proteins, which stabilizes the repressive effect of ETV6 on 
transcription through a HDAC (histone deacetylase) independent 
mechanism [22]. In contrast, repression by the central domain is 
mediated through binding of various co-repressors, including SMRT, 
mSin3A, N-CoR and Tip60, which subsequently recruit HDACs to 
mediate transcriptional repression [17-21].
While ETV6 would appear to regulate the transcription of genes 
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Introduction
ETV6 (ETS variant 6) also known as TEL1 (Translocating E26 
transforming-specific leukemia 1) and the related ETV7 or TEL2 are 
members of the evolutionarily-conserved ETS (E26-transforming 
specific) family of transcription factors, which have been implicated 
in a variety of cellular development and differentiation processes 
[1,2]. All ETS proteins share an extensively conserved domain of 
about 85 amino acids, which binds to purine-rich sequences within 
the promoters or enhancers of target genes, utilizing a GGAA/T 
sequence that is flanked by 5-8 nucleotide, thus determining the 
specificity of each family member [3,4]. This so-called ETS domain 
represents a winged helix-turn-helix domain composed of 3 α-helixes 
and 4 β-sheets arranged in the order α1-β1-β2-α2-α3-β3-β4 [5]. 
Another evolutionary conserved domain shared by a subset of ETS 
family members is the Pointed (PNT) domain, which is in the form of 
a modified Helix-Loop-Helix (HLH) structure for mediating protein-
protein interactions [6]. Although some ETS family members are 
expressed ubiquitously, others are predominantly expressed in a 
tissue-specific manner [7], including in hematopoietic cells where 
they regulate blood cell development [8]. 
ETV6 gene and protein structure and function
The human ETV6 gene spans a region of over 240 kb on the short 
(P) arm of chromosome 12 at band 13.1 and consists of 8 exons [9]. 
There are two isoforms of ETV6 (57 kDa and 53 kDa) arising from 
alternative start codons in exon 1a (Figure 1) [10]. The PNT domain 
at its N-terminus is encoded by exons 3 and 4 and the ETS domain at 
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Figure 1: ETV6 chromosomal location, gene and protein structure. 
Schematic representation of the ETV6 gene locus on human chromosome 12 
(upper panel), the ETV6 gene transcript with numbered boxes corresponding 
to exons (middle panel), and the ETV6 protein with domains indicated and 
relevant amino acids numbered (lower panel).
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with ETS consensus sites in their promoters, only a handful of genes 
actually targeted by ETV6 are known. These include the GPIIb and 
GPIbα genes in myeloid K562 cells induced with TPA [23], the TCL1 
(T-cell lymphoma 1) oncogene in pre-B cell acute lymphoblastic 
leukemia cells [24], the BCL-XL gene in NIH 3T3 cells [13] and 
β-globin in transgenic mice expressing human ETV6 under the 
control of the Gata1 promoter [25] as well as acting on the Stromelysin 
(MMP3) promoter in Ras-transformed NIH3T3 cells [26]. 
Role of ETV6 in vivo
ETV6 has been shown to play an important role in normal 
embryonic development and hematopoietic regulation. Targeted 
knockout of the Etv6 gene in mice led to embryonic lethality at 
day 10.5-11.5 of development due to mesenchymal and neural cell 
apoptosis accompanied by defective angiogenesis in the yolk sac [27]. 
Primary erythropoiesis at this time was unaffected. However, further 
analysis of chimerical mice consisting of Etv6-/- cells and normal 
(Etv6+/+) cells revealed that although Etv6-/- cells contributed to yolk 
sac and fetal liver hematopoisis, they were totally absent from the 
bone marrow. These findings revealed that Etv6 was essential for the 
establishment of definitive hematopoisis in mice [28]. Knockdown 
of etv6 in Xenopus also revealed a requirement for this gene in the 
formation of the first definitive hematopoietic stem cells in the dorsal 
aorta [29]. Conditional knockouts in adult mice indicated that Etv6 
was essential for survival of adult HSCs within hematopoietic niches 
[30]. However, ablation of Etv6 after lineage commitment did not 
affect adult hematopoietic except for specific maturation defects in 
the megakaryocytic lineage [30].
In contrast, transgenic mice expressing human ETV6 under the 
control of Gata1 promoter revealed that ETV6 was also involved 
in both proliferation and differentiation in the erythroid lineage, 
depending on the stage of erythroid development. During the early 
stages of erythropoiesis, ETV6 was found to accelerate proliferation, 
while in the latter stages it increased differentiation including 
stimulation of hemoglobin synthesis. The latter was achieved through 
indirect promotion of ALAS-E transcription and direct stimulation 
of β-globin synthesis [25]. This may explain the observation that 
enhanced expression of ETV6 in mouse erythroleukemia cells 
induced their differentiation toward erythrocytes [31]. Recent studies 
in zebrafish have confirmed a broad role for ETV6 in embryonic 
hematopoiesis, impacting on progenitor cells, as well as erythroid, 
myeloid and lymphoid populations [32].
Chromosomal translocations involving ETV6 in 
hematological malignancy
The human ETV6 gene is notable for its frequent involvement 
in chromosomal translocations associated with hematological 
malignancies. Approximately 50 translocations involving the ETV6 
gene have been described, involving around 30 partner genes [33]. 
These translocations can be classified according to the type of fusion 
partners namely: tyrosine kinases, transcription factors and other 
proteins (Figure 2). 
Tyrosine kinases: The ETV6/tyrosine kinase fusions have been 
detected in a plethora of hematological malignancies. In all cases, 
including fusions with ABL1, ABL2, JAK2, SYK, FRK, LYN, FGFR3, 
PDGFRA, PDGFRB, NTRK3 and FLT3, the PNT domain of ETV6 
is fused to the tyrosine kinase domain of the fusion partner. In 
this way the PNT domain mediates dimerization of the tyrosine 
kinase, resulting in its constitutive activation with subsequent 
autophosphorylation and phosphorylation of downstream signal 
transducing proteins, such as STATs (Table 1). The use of animal 
models has revealed new insights into the function of these fusion 
oncoproteins, for example ETV6-JAK2 [34,35]. 
Transcription factors: ETV6/transcription factor fusions have been 
implicated in variety of leukemias. In these cases, the fusion modifies 
the transcription activity of ETV6 and/or the fusion partner by 
converting a transcriptional repressor into an activator or vice 
versa, which can be achieved in three different ways. Fusions with 
involvement of the PNT domain of ETV6, such as fusions with 
RUNX1 and ARNT, result in a dominant-negative effect of the fusion 
protein over the normal function of the fusion partner. However, in 
fusions that involve both PNT and ETS domains of ETV6, such as 
fusions with MN1, PAX5 and HLXB9, the chimeric protein appears 
to act as an aberrant transcription factor and results in modification 
of both ETV6 and partner protein transcription activity. Finally, in 
fusions that involve the promoter – rather than a functional domain 
– of ETV6, such as with EVI1 and CDX2, ectopic expression of the 
fusion partner genes in hematopoietic cells has been suggested to 
mediate leukemogenesis (Table 2).
Other proteins: Other ETV6 translocations not involving tyrosine 
kinases or transcription factors have been reported in variety of 
leukemias. In most of these cases, just the first two exons of ETV6 
are involved in the translocation. It is believed that in these cases, 
involving fusions to CHIC2, MDS2, TTL, STL, ACS2 and PER1, 
the over expression of a neighboring gene is the critical pathogenic 
mechanism of the translocation (Table 3). 
Tumor suppressor function of ETV6
Besides being involved in a vast number of translocations 
associated with hematological malignancies, there are other studies 
supporting the notion that ETV6 functions as a tumor suppressor 
gene. The short arm of chromosome 12 is a hot spot for chromosomal 
abnormalities in various hematological malignancies, these include 
interstitial deletions that lead to the loss of genetic material from 12p 
Figure 2: ETV6 fusion partner network. 
Graphical representation of the various proteins found fused to ETV6 in 
malignancy are shown by class: tyrosine kinases (blue), transcription factors 
(green) and other proteins (orange).
J Blood Disord 1(3): id1012 (2014)  - Page - 03
Alister C Ward Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
which has been mapped to a small locus containing the ETV6 and KIP1 
genes [36]. In many cases of childhood ALL carrying t(12;21) the wild-
type ETV6 allele is deleted [9,37,38]. Interestingly, in cells harboring 
these translocations, consistent loss of ETV6 expression was observed 
even in the absence of detectable ETV6 deletion, suggesting that 
secondary structural abnormalities and epigenetic modifications may 
lead to the silencing of ETV6 alleles [38]. Frequent point mutations 
of ETV6 have been reported in T-ALL and AML leading to truncated 
forms of ETV6 which exerted a dominant-negative effect to abolish 
wild type ETV6 function [39-41]. Furthermore, in several cases of 
leukemia including ETV6 translocations, neither functional fusion 
protein was identified nor was ectopic expression of a neighboring 
proto-oncogene reported. In these cases, haploinsufficiency of ETV6 
has been raised as a contributing factor in the etiology of leukemia 
[42,43].
Additional evidence of a potential tumor suppressor role for 
ETV6 comes from its functional studies. A transient increase in 
endogenous ETV6 expression was also reported during the first 
3 days of differentiation of Mouse Erythroleukemia (MEL) cells 
[31]. Over-expression of ETV6 in these cells enhanced erythroid 
differentiation while introduction of a dominant-negative mutant 
of ETV6 completely blocked this process with cells continuing to 
proliferate. Enforced expression of ETV6 inhibited cell growth in Ras-
transformed cells [26] and retarded proliferation of both primary wild 
type and immortalized cells possibly through inducing G1 arrest [44] 
or decreasing survival via direct repression of the Bcl-XL promoter 
Fusion gene Disease Translocation Breakpoint in ETV6 PNT ETS Functional mechanisms References
ETV6-ABL1 AML, B-cell ALL, T-cell ALL, MPN, CML (Ph negative) in CP and BP t(9;12) int 4 or 5 + -
• Constitutive activation of PTK 
domain of ABL1 [45-49]
ETV6-ABL2 AML-M4, M3, T-cell ALL t(1;12) int 5 + - • Constitutive activation of PTK domain of ABL2 [50-52]
ETV6-JAK2 Pre-B cell ALL, aCML, T-cell ALL t(9;12) int 4 or 5 + - • Constitutive activation of PTK 
domain of JAK2
[53,54]
ETV6-FGFR3 Peripheral T-cell lymphoma t(4;12) int 5 + - • Constitutive activation of PTK domain of FGFR3 [55]
ETV6-SYK MDS t(9;12) int 5 + - • Constitutive activation of PTK 
domain of SYK
[56]
ETV6-FRK AML-M4 t(6;12) int 4 + - • Constitutive activation of PTK 
domain of FRK
[57]
ETV6-LYN Primary myelofibrosis Ins(12;8) int 5 + - • Constitutive activation of PTK domain of LYN [58]
ETV6-
PDGFRA MPN t(4;12) int 6 + -
• Constitutive activation of PTK 
domain of PDGFRA [59]
ETV6-
PDGFRB
CMML, AML-M0 on CIM, AML-M2, aCML 
in Bc t(5;12) int 4 or 7 + -
• Constitutive activation of PTK 
domain of PDGFRB [59-62]
ETV6-NTRK3 AML-M2, M0, CEL t(12;15) int 4 or 5 + - • Constitutive activation of PTK 
domain of NTRK3
[63-65]
ETV6-FLT3 MPN with hypereosinophilia, T-lymphoblastic lymphoma t(12;13) int 4 or 5 + -
• Constitutive activation of PTK 
domain of FLT3 [66,67]
Table 1: Tyrosine kinase fusions with ETV6. 
Summary of the ETV6 fusions with tyrosine kinases, indicating the disease, translocation, ETV6 breakpoint, ETV6 domain involvement (PNT, ETS), functional 
mechanisms and references.
AML: Acute Myelogenous Leukemia; ALL: Acute Lymphocytic Leukemia; MPN: Myeloproliferative Neoplasm; CML: Chronic Myelogenous Leukemia; Ph: Philadelphia 
chromosome; CP: Chronic Phase; BP: Blastic Phase; aCML: atypical CML; MDS: Myelodysplastic Syndrome; CMML: Chronic Myelomonocytic Leukemia; CIM: 
Chronic Idiopathic Myelofibrosis; Bc: Blastic crisis; CEL: Chronic Eosinophilic Leukemia
Fusion gene Disease Translocation Breakpoint in ETV6 PNT ETS Functional mechanisms References
ETV6-RUNX1 B-cell ALL t(12;21) int 4 or 5 + -
• Dominant negative effect of the fusion 
protein over wild type ETV6 allele
• Repression of RUNX1 target genes
[37,68,69]
MN1-ETV6 AML-M0, M2, M4, CML, RAEB, AML on MDS t(12;22) int 2 or 3 + +
• Activation of ETV6 target genes
• Repression of retinoic acid mediated 
transcription
• Dominant negative effect of the fusion 
protein over wild type MN1 allele
[70-76]
ETV6-ARNT AML-M2, T-cell ALL t(1;12) int 4 + -
• Dominant negative effect of the fusion 
protein over wild type ETV6 allele
• Modification of ARNT into a transcriptional 
repressor
[77,78]
ETV6-EVI1 aCML, Bc-CML, RAEB, AML-M0 t(3;12) int 2 - - • Ectopic expression of EVI1 [53,79,80]
ETV6-CDX2 AML-M1 t(12;13) int 2 - - • Ectopic expression of CDX2 [50,81]
PAX5-ETV6 B-cell ALL t(9;12) int 2 + + • Modification of ETV6 and/or PAX5 transcription activity [82,83]
HLXB9-ETV6 AML-M0, M1, M2,  M3, M7 t(7;12) int 2 + + • Modification of ETV6 and/or HLXB9 transcription activity? [84-87]
Table 2: Transcription factor fusion partners of ETV6. 
Summary of the ETV6 fusions with other transcription factors, as detailed in Table 1.
ALL: Acute Lymphocytic Leukemia; AML: Acute Myelogenous Leukemia; RAEB: Refractory Anemia with Excess of Blasts; MDS: Myelodysplastic Syndrome; aCML: 
atypical Chronic Myelogenous Leukemia; Bc-CML: Blastic Crisis of CML
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[13]. It has also been demonstrated that ETV6 over expression slowed 
the Ras-induced tumor formation in nude mice [44].
Conclusion
ETV6 remains best known for its role as a hot spot for 
translocation, yielding a large number of chromosomal fusions 
important in the etiology of hematological malignancy. However, 
more recent studies have indicated that the encoded protein is both 
a tumor suppressor and an important regulator of hematopoiesis, 
which provides new insights into how its disruption contributes to 
malignancy. Key questions remaining for future research are, firstly, 
which genes are targeted by ETV6 in both its tumor suppressor and 
oncogenic roles and, secondly, whether pharmacologic agents can be 
developed to either enhance the former or hinder the latter.
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